-
EP3759125
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3759125
| EP3759125 - METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 04.12.2020 Database last updated on 31.08.2024 | |
| Former | The international publication has been made Status updated on 07.09.2019 | Most recent event Tooltip | 27.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US | [2021/01] | Inventor(s) | 01 /
FREEMAN, Gordon J. 305 Walnut Street Brookline, MA 02445 / US | 02 /
XIAO, Yanping 60 Babcock Street, Apt. 66 Brookline, MA 02446 / US | [2021/01] | Representative(s) | Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE | [N/P] |
| Former [2021/01] | Helbig, Christian Wagner + Helbig Patentanwälte Pfarrstrasse 14 80538 München / DE | Application number, filing date | 19760261.8 | 27.02.2019 | [2021/01] | WO2019US19724 | Priority number, date | US201862636236P | 28.02.2018 Original published format: US 201862636236 P | [2021/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019168897 | Date: | 06.09.2019 | Language: | EN | [2019/36] | Type: | A2 Application without search report | No.: | EP3759125 | Date: | 06.01.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.09.2019 takes the place of the publication of the European patent application. | [2021/01] | Search report(s) | International search report - published on: | US | 17.10.2019 | (Supplementary) European search report - dispatched on: | EP | 09.11.2021 | Classification | IPC: | C07K14/43, C07K14/435, C07K14/705, A61K38/17, A61K39/395, A61K31/7105, A61K38/00, A61K45/06, A61K39/00, A61P37/00, A61P35/00, C07K14/74, C07K16/28, G01N33/50, G01N33/574, A61P1/00 | [2021/49] | CPC: |
C07K14/705 (EP);
C07K16/2803 (EP,US);
A61K31/7088 (US);
A61K31/7105 (EP);
A61K39/3955 (US);
A61K45/06 (EP,US);
A61K47/6849 (US);
A61K47/6863 (US);
A61P1/00 (EP);
A61P35/00 (EP,US);
A61P37/00 (EP);
C07K14/435 (EP);
C07K14/70503 (EP);
C07K14/70539 (EP);
C07K16/2818 (EP,US);
C12N15/1138 (US);
C12N15/115 (US);
G01N33/5011 (EP,US);
G01N33/5088 (US);
G01N33/574 (EP);
G01N33/57492 (US);
A61K2039/505 (EP);
A61K2039/507 (EP,US);
A61K38/00 (EP);
C07K2317/21 (US);
C07K2317/51 (US);
C07K2317/515 (US);
C07K2317/52 (US);
C07K2317/565 (US);
C07K2317/72 (US);
C07K2317/73 (US);
C07K2317/76 (US);
C07K2317/80 (US);
C07K2317/92 (US);
C12N2310/11 (US);
C12N2310/16 (US);
|
| Former IPC [2021/01] | C07K14/43, C07K14/435, C07K14/705, A61K38/17, A61K39/395 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/01] | Extension states | BA | 24.09.2020 | ME | 24.09.2020 | Title | German: | VERFAHREN ZUR KREBSBEHANDLUNG UNTER VERWENDUNG VON KOMBINATIONEN AUS ANTI-BTNL2 UND IMMUNCHECKPOINT-BLOCKIERUNGSREAGENZIEN | [2021/01] | English: | METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS | [2021/01] | French: | MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE DE COMBINAISONS D'AGENTS DE BLOCAGE ANTI-BTNL2 ET POINTS DE CONTRÔLE IMMUNITAIRES | [2021/01] | Entry into regional phase | 24.09.2020 | National basic fee paid | 24.09.2020 | Search fee paid | 24.09.2020 | Designation fee(s) paid | 24.09.2020 | Examination fee paid | Examination procedure | 24.09.2020 | Examination requested [2021/01] | 07.06.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 25.02.2021 | Renewal fee patent year 03 | 25.02.2022 | Renewal fee patent year 04 | 27.02.2023 | Renewal fee patent year 05 | 27.02.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP1702622 (CONARIS RES INST AG [DE]) [Y] 1-15 * the whole document *; | [Y]WO2008154516 (REGENTS THE UNIVERSTITY OT TEX [US], et al) [Y] 1-15 * the whole document *; | [Y] - HEATHER A. ARNETT ET AL, "Immune modulation by butyrophilins", NATURE REVIEWS IMMUNOLOGY, GB, (20140725), vol. 14, no. 8, doi:10.1038/nri3715, ISSN 1474-1733, pages 559 - 569, XP055352130 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/nri3715 | [Y] - LUCIE ABELER-DRNER ET AL, "Butyrophilins: an emerging family of immune regulators", TRENDS IN IMMUNOLOGY, vol. 33, no. 1, doi:10.1016/J.IT.2011.09.007, ISSN 1471-4906, (20120101), pages 34 - 41, (20110922), XP028122722 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.it.2011.09.007 | [A] - YANXIA GUO ET AL, "Novel Immune Check-Point Regulators in Tolerance Maintenance", FRONTIERS IN IMMUNOLOGY, (20150818), vol. 6, doi:10.3389/fimmu.2015.00421, XP055443686 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.3389/fimmu.2015.00421 | International search | [Y]WO03074654 (SIRNA THERAPEUTICS INC [US], et al) [Y] 5, 6 * Abstract, pg 12, Table V *; | [Y]US2004209289 (BAUM PETER R [US], et al) [Y] 4, 7 * Especially para [0126], [0136], [0171] *; | [Y]WO2016085662 (EINSTEIN COLL MED [US]) [Y] 11* Especially para [0010], [0035] *; | [XY]US2017121409 (VERONA RALUCA [US], et al) [X] 1-3, 8-10 * Especially para [0006], [0101], [0112], [1434], [1538], [1540], [1572] * [Y] 4-7, 11 |